Tvardi Therapeutics, Inc. (TVRD)
Nasdaq: TVRD · Pharmaceutical Preparations · Sugar Land, TX · filing with the SEC since 2005
Who owns Tvardi Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Sporos Bioventures LLC holds 8.95% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G filed Aug 8, 2025 says.
Directors and officers
9
report now, of 30 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Sporos Bioventures LLC
SCHEDULE 13G · filed Aug 8, 2025 · Common Stock, par value $0.001 per share
Solas Tvardi Sidecar LLC
SCHEDULE 13G · filed Apr 22, 2025 · Common Stock of Tvardi Therapeutics, Inc.
Slate Path Capital LP
SCHEDULE 13G · filed Aug 14, 2025 · Common stock, par value $0.001 per share
David J. Tweardy
SCHEDULE 13G · filed May 2, 2025 · Common Stock, par value $0.001 per share
Ronald A. DePinho
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.7% in Nov 14, 2025
Samuel D. Tweardy
SCHEDULE 13G/A · filed Aug 5, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 10.1% in May 2, 2025
Vifor (International) Ltd.
SCHEDULE 13D/A · filed Apr 16, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 13.5% in Dec 18, 2024
What TVRD reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Cara Therapeutics, Inc
An entity · legal entity · owns, named in the 10-K filed Mar 31, 2026
Legacy Tvardi
A company bought · acquisition · owns, named in the 10-K filed Mar 31, 2026
Legacy Tvardi Convertible Notes
A company bought · acquisition · owns, named in the 10-K filed Mar 31, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 6, 2024.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.